Allergan PLC (NYSE:AGN) has received the US Food and Drug Administration (FDA) approval for the use of Botox for the temporary improvement of moderate-to-severe forehead lines.
The latest approval makes the brand the first and only neurotoxin to be indicated for three facial treatment areas. It has already been approved for the treatment of "crow's feet" and glabellar lines.
READ: Allergan shares puff up in pre-market as it announces latest share buy-back and reaffirms dividend commitment
In a statement released today announcing the FDA approval, David Nicholson, the company’s chief research and development officer said: “Allergan recognizes that forehead lines are a top area of concern for patients.”